Business Description
Neuronetics Inc
NAICS : 621511
SIC : 8099
ISIN : US64131A1051
Description
Neuronetics Inc a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulations, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advanced Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address many of the key limitations of existing treatment options.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.97 | |||||
| Equity-to-Asset | 0.3 | |||||
| Debt-to-Equity | 1.83 | |||||
| Debt-to-EBITDA | -2.68 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -3.11 | |||||
| Beneish M-Score | -2.35 | |||||
| WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -1.6 | |||||
| 3-Year EBITDA Growth Rate | 16 | |||||
| 3-Year EPS without NRI Growth Rate | 9.4 | |||||
| 3-Year FCF Growth Rate | 8.1 | |||||
| 3-Year Book Growth Rate | -4.1 | |||||
| Future 3-5Y Total Revenue Growth Rate | 13.03 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 18.8 | |||||
| 9-Day RSI | 27.59 | |||||
| 14-Day RSI | 35.75 | |||||
| 6-1 Month Momentum % | 340.97 | |||||
| 12-1 Month Momentum % | 113.15 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.73 | |||||
| Quick Ratio | 4.33 | |||||
| Cash Ratio | 3.06 | |||||
| Days Inventory | 166.28 | |||||
| Days Sales Outstanding | 68.55 | |||||
| Days Payable | 71.06 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -15 | |||||
| Shareholder Yield % | -5.82 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 72.47 | |||||
| Operating Margin % | -42.82 | |||||
| Net Margin % | -42.31 | |||||
| FCF Margin % | -48.5 | |||||
| ROE % | -67.68 | |||||
| ROA % | -28.5 | |||||
| ROIC % | -67.89 | |||||
| ROC (Joel Greenblatt) % | -147.43 | |||||
| ROCE % | -29.41 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 1.42 | |||||
| PB Ratio | 3 | |||||
| Price-to-Tangible-Book | 2.98 | |||||
| EV-to-EBIT | -4.18 | |||||
| EV-to-EBITDA | -4.55 | |||||
| EV-to-Revenue | 1.49 | |||||
| EV-to-Forward-Revenue | 1.35 | |||||
| EV-to-FCF | -3.12 | |||||
| Price-to-Net-Current-Asset-Value | 8.32 | |||||
| Earnings Yield (Greenblatt) % | -23.9 | |||||
| FCF Yield % | -32.98 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers